| Alexis A Albrecht, APRN | |
|
430 N Monitor St, West Point, NE 68788-1595 | |
| (402) 372-6717 | |
| Not Available |
| Full Name | Alexis A Albrecht |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Psychiatric/mental Health |
| Location | 430 N Monitor St, West Point, Nebraska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457089435 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | 114333 (Nebraska) | Primary |
| Entity Name | Franciscan Care Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043224975 PECOS PAC ID: 4284624909 Enrollment ID: O20040514000822 |
News Archive
Today the peer-reviewed journal Women's Health Issues (WHI) released a new Special Collection on Women's Heart Health, with a focus on improving healthcare services to women at risk for cardiovascular disease.
According to the Australian Nurses Federation (ANF) there are more than 18,000 reports of accidental needle stick injuries to nurses caused by syringes or other sharp items in Australia each year. This increases their risk of contracting deadly blood borne diseases like HIV/AIDS, hepatitis B and C etc. The authorities believe that these figures although alarming are not reflective of the true figures with many nurses choosing to keep their exposure under wraps.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.
It's not a cure, but this may be some of the best news patients infected with the hepatitis C virus (HCV) have heard in a long time: A new drug, eltrombopag, appears to be effective in boosting low platelet counts, one of the major reasons why patients can't endure antiviral treatments.
› Verified 9 days ago
| Entity Name | Franciscan Care Services Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1588673578 PECOS PAC ID: 4284624909 Enrollment ID: O20071128000231 |
News Archive
Today the peer-reviewed journal Women's Health Issues (WHI) released a new Special Collection on Women's Heart Health, with a focus on improving healthcare services to women at risk for cardiovascular disease.
According to the Australian Nurses Federation (ANF) there are more than 18,000 reports of accidental needle stick injuries to nurses caused by syringes or other sharp items in Australia each year. This increases their risk of contracting deadly blood borne diseases like HIV/AIDS, hepatitis B and C etc. The authorities believe that these figures although alarming are not reflective of the true figures with many nurses choosing to keep their exposure under wraps.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.
It's not a cure, but this may be some of the best news patients infected with the hepatitis C virus (HCV) have heard in a long time: A new drug, eltrombopag, appears to be effective in boosting low platelet counts, one of the major reasons why patients can't endure antiviral treatments.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alexis A Albrecht, APRN 430 N Monitor St, West Point, NE 68788-1595 Ph: (402) 372-6717 | Alexis A Albrecht, APRN 430 N Monitor St, West Point, NE 68788-1595 Ph: (402) 372-6717 |
News Archive
Today the peer-reviewed journal Women's Health Issues (WHI) released a new Special Collection on Women's Heart Health, with a focus on improving healthcare services to women at risk for cardiovascular disease.
According to the Australian Nurses Federation (ANF) there are more than 18,000 reports of accidental needle stick injuries to nurses caused by syringes or other sharp items in Australia each year. This increases their risk of contracting deadly blood borne diseases like HIV/AIDS, hepatitis B and C etc. The authorities believe that these figures although alarming are not reflective of the true figures with many nurses choosing to keep their exposure under wraps.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.
It's not a cure, but this may be some of the best news patients infected with the hepatitis C virus (HCV) have heard in a long time: A new drug, eltrombopag, appears to be effective in boosting low platelet counts, one of the major reasons why patients can't endure antiviral treatments.
› Verified 9 days ago
Allison M Bramlet, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 500 E Decatur St, West Point, NE 68788 Phone: 402-372-2477 Fax: 402-372-6770 | |
Ms. Pamela H List, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 500 East Decatur, West Point, NE 68788 Phone: 402-372-2477 Fax: 402-372-6770 | |
Mary F Brockmann, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 500 E Decatur St, West Point, NE 68788 Phone: 402-372-6717 | |
Miss Abby D Preszler, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 430 N Monitor St, West Point, NE 68788 Phone: 402-372-6717 | |
Julia Eilerts, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 540 E Washington St, West Point, NE 68788 Phone: 402-372-1118 |